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Abstract 
Aim: Neurological involvement related to HIV-1 infection is well described in the paediatric 
population and causes significant morbidity and mortality. This study aimed to describe 
specific neurological and neurobehavioural complications in this population. 
 
Method: Children infected with HIV-1 attending infectious diseases clinics were recruited for 
general and neurological assessments, developmental history screening and categorization 
of behavioural phenotype using the Aberrant Behaviour Checklist (ABC).  
 
Results: Eighty patients were assessed (males-44/80: females- 36/80) (median age 5 years 1 
month; range: 3 months - 12 yrs). Eighteen patients (23%) were not on antiretroviral (ARV) 
therapy at the time of testing. The Centre for Disease Control (CDC) immune categories of 
the patients at the time of assessment were: Category 1- n=6/80, Category 2- n=15/80 and 
Category 3- n=59/80. Thirty-three percent had a history of chronic lung disease, 10% had a 















Anthropometric measurements identified that 19% of the patients were microcephalic, 17% of 
the patients were <60% of their expected weight, 49% were 60-80% of expected weight and 
45% were stunted. On neurological assessment 41% of the patients had global pyramidal 
tract signs, 7% had a hemiparesis, 5% had peripheral neuropathy, 16% had visual 
impairment, and 6% were hearing impaired. Of those who were screened for developmental 
deficits (patients <6years of age) 66% had gross motor delay, 75% had fine motor delay, 70% 
had language delay and 73% had cognitive delay. Forty one percent had HIV 
Encephalopathy, 81% of whom a CD4 count <15% and 48% were < 1year old. 
On the aberrant behaviour checklist (ABC) scale 24/80 patients had features of hyperactivity 
and 22/80 patients scored in the mild-moderate range on the lethargy / social withdrawal sub-
scale reflecting a correlation with the affective and adjustment disorders.  
 
Conclusion: Diverse neurological and neurobehavioural deficits are common in children with 
HIV-1 infection especially those with CD4 <15%, not on ARVs, with growth impairment and 
<1yr of age. This study demonstrated the extent and spectrum of neurobehavioural and 
neurological complications in a defined HIV population. It stresses the need for early initiation 
of ARVs in the planning for future regimens and guidelines. 
 
Key for Abbreviations 
ABC Scale- Aberrant Behaviour Checklist Scale    PI- Protease Inhibitor    
AIDS- Acquired Immunodeficiency Syndrome       PHE- Progressive HIV Encephalopathy    
ART- Antiretroviral Therapy                                   TB- Tuberculosis                       
CDC- Centre for Disease Control                         TBM- Tuberculous Meningitis 
CMV- Cytomegalovirus                                         UWFA- Under weight for age 
CNS- Central Nervous System                             WHO- World Health Organisation  
CT scan- Computerised Tomography scan 
DdI- Didanosine  
HAART- Highly active antiretroviral therapy                     
HAD- HIV-Associated Dementia    
HIV-1 – Human Immunodeficiency Virus 1     
HIVE- HIV encephalopathy 
MRI-Magnetic Resonance Imaging 
NCS- Nerve conduction studies 
 
PCR-Polymerase Chain Reaction 



















At the end of 2007 an estimated 2.1 million children were infected with human 
immunodeficiency virus (HIV), 1.8 million (85.7%) of whom lived in sub-
Saharan Africa and 280,000 (13.3%) in South Africa.  At the end of 2008 
275,000 children were on antiretroviral therapy (ART) in low-and middle-
income countries. The number on ART in South Africa was 94,000, 
representing a coverage rate of 61% of all children in need of ART.1
 
 Global 
commitments to improve access to antiretroviral (ART) therapy, education 
campaigns and prevention of mother to child transmission of HIV has reduced 
the rates of paediatric HIV transmission in the developed world. However the 
epidemic continues to escalate in sub-Saharan Africa and parts of Asia where 
there is limited access to ART.  
HIV-1 invades the CNS early in the course of infection. 




1. HIV may be carried into the brain by infected macrophages-monocytes 
and CD4+ T lymphocytes (the “Trojan horse effect”);  
  
2. Cell-free virus may pass from the vascular compartment into brain tissue 
between cerebral microvascular endothelial cells; 
3. Following direct HIV infection of the endothelial cells of the blood/brain 
barrier, newly formed HIV viral particles may be released into the cerebral   
compartment; 
4. Lipopolysaccharides have been implicated  as markers of microbial gut  
     translocation which lead to chronic immune activation and HIV   
     progression.4
     bacteria, undergo translocation from the gut through a “Leaky” gut barrier.  
 Plasma endotoxins, derived from Gram-negative    
     These endotoxins are thought to cause immune activation in  
     HIV infection. Elevated lipopolysaccharide levels are implicated in  














     part of the pathogenesis of HIV- Associated Dementia (HAD).
 
5 
Once within the nervous system the virus infects other cell lines which 
include perivascular macrophages, astrocytes and microglia.6 This 
inflammatory response induces apoptotic pathways causing neuronal loss. 
Apoptosis may be activated by viral glycoproteins gp120, tat, nef, vpr and 




Neurological involvement related to HIV-1 infection is well described in the 
paediatric population and causes significant morbidity and mortality .8 At least 
50% of HIV-1 infected children show neurological symptoms and signs during 
the course of the disease.9 Involvement of the central nervous system (CNS) 
may be the initial manifestation of AIDS in up to 18% of children and may be 
the only manifestations of AIDS in 26% of these children.
Neurological manifestations of AIDS may be due to: 
10, 11 
a. Direct neuronal infection by the virus and the cytokine mediated effects of 
the virus that lead to neurotoxicity. Perinatally infected children show early 
signs of HIV-1 encephalopathy. This may be because the virus influences the 
neuro-ontogenetic processes during early brain development.2 Active CNS 
viral replication, which may co-incide with systemic HIV disease, results in 
progressive HIV encephalopathy (PHE).  Neurological signs can occur before 
immune suppression.
b. Immune dysregulation results in the child becoming vulnerable to other 
complications and sequelae including opportunistic infections, malignancies 
and cerebrovascular disease. 
12 
c. The side effects from drugs. 
d. The effects of socio-economic problems like malnutrition, being AIDS 
orphans and environmental deprivation. 
















The spectrum of neurological manifestations of the disease is diverse. 
Encephalopathy is the commonest manifestation and was reported as 
between 30-50% for progressive encephalopathy and up to 90% for static 
encephalopathy in the pre-treatment era. 
Other complications include developmental delay (42%) 
13, 14 
13, opportunistic 
infections (33%), 13 strokes (1.3-2.6%), 15 seizures (6-13%), 12 CNS 
lymphomas (2-6%)15  and peripheral nervous system disease.13 Behavioural 
problems  and attention deficit hyperactivity disorder 12 are also reported to be 
frequent amongst these children. Anxiety and conversion disorders are 




There is limited data on the prevalence of specific neurological complications 
in children with HIV-1 in Africa. A study of Rwandan children between 6 
months and 2 years of age found that 40% of HIV-infected children had an 
abnormal neurodevelopmental examination at 18 months compared with only 
5% of HIV-exposed uninfected children.17 Van Rie et al18 documented 
moderate to severe delay in mental, motor, and language development  in the 
majority of HIV-infected children in Kinshasa. Another study in the Democratic 
Republic of Congo documented developmental impairment in both 
asymptomatic HIV-infected children and HIV-exposed, uninfected children 
supporting the theory that an environmental factor may be contributing to the 
developmental delay.19 Abubakar et al in their systematic review of 6 studies 
in sub-Saharan Africa reported severe motor impairment and moderate 
cognitive impairment at 18 months of age in HIV-1 infected children. 20 Smith 
et al showed a significant rate of early neurocognitive, language and motor 
developmental disabilities in a group of HIV-infected South African children.
 
21 
The HIV-1 c subtype is the predominant virus causing infection in southern 
Africa as well as globally;22
 
 hence the neurological disorders described herein 


















This study aimed to describe the specific neurological, neurodevelopmental 
and behavioural complications, in a cohort of HIV positive children attending 
dedicated infectious disease clinics.  
 
Objective 
The profile obtained will identify problem areas in the current treatment 
regimens and will provide guidelines for the design of future holistic treatment 
protocols; i.e. should we start HAART earlier in children with HIV 
encephalopathy and should guidelines be formulated for the social, emotional 
and educational management of these children? The study will provide the 
basis for future prospective studies in the areas of neurodevelopment and 
psychosocial issues and will contribute towards the development of guidelines 
for referral to specialist centres to assist primary health care physicians.  
 
Methods 
Children between 1 month and 12 years of age were prospectively recruited 
from Infectious Disease Clinics at the Red Cross Children’s Hospital and 
Groote Schuur Hospital (April 2006 - January 2007). Of the 30-35 patients 
attending each clinic, the first 6-8 patients per clinic were recruited for 
assessment. To reduce bias the investigator was blinded to the contents of 
the folders prior to recruiting the patients. 
Patients underwent a full general and neurological examination by the 
principle investigator (a child neurologist). Patients were referred for specialist 
investigations as clinically indicated. 
The Red Cross Children’s Hospital is a paediatric tertiary centre and a referral 
base for patients throughout the Western Cape of South Africa. The patients 




















Group demographics and specific relevant information of children attending 
the Infectious Diseases Clinic at Red Cross Children’s Hospital and the 
Kidzpositive clinic at Groote Schuur Hospital were prospectively recorded to 
document data including age, sex, whether or not they were on HAART, date 
of commencement, and regimen, CD4 counts and viral loads at diagnosis, at 
start of HAART and the most recent viral load. Social demographics including 
family structure, caregiver, congruence of home and culture, language and 
school details were documented. Information was recorded in Appendix 1. 
 
Clinical assessment included developmental screening, growth parameters 
and neurological examination. Patients under 6 years of age were classified 
as either developmentally delayed or not, compared to age appropriate 
developmental milestones modified from the Denver II Developmental 
Screening Test.23 (See Appendix 2) The Denver ll Developmental Screening 
Test is a screening tool to identify children (birth to 6 years) at risk for 
developmental problems from those who are developmentally normal. 23 This 
was simplified as a practical tool to identify those children who had obvious 
deficits. HIVE was defined as at least 1 of the following findings present for at 
least 2 months (with no concurrent illness to explain the findings): a) failure to 
attain/loss of developmental milestones, verified by standard developmental 
scale; b) impaired brain growth or acquired microcephaly demonstrated by 
head circumference measurement or neuro-imaging; c) acquired symmetric 
motor deficit affecting a child >1 month of age.24 The caregiver completed the 
Aberrant Behaviour Checklist (ABC). (Appendix 3) The Aberrant Behaviour 
Checklist (ABC) 25 is a rating scale that was developed primarily to measure 
the effects of pharmacological intervention in individuals living in residential 
facilities but is widely used to monitor behaviour problems in other 
populations. It is a third-party informant questionnaire consisting of five 















has been validated and recommended for children and adolescents with dual 
diagnosis .26
Interpreters were used for non-English speaking and illiterate care-givers and 
patients.   
 It relies on clinical observations of behaviour without regard for 
the underlying aetiology or function of the observed behaviour. 
Children were referred for audiology, neurophysiology, neuro-imaging, formal 
developmental assessment and or psychiatric assessment as indicated by the 
clinical needs of the child. Further investigations including 
electroencephalogram, nerve conduction studies and neuro-imaging were 
directed by the clinical needs of the child. 
 
Ethics/consent  
 Written consent (Appendix 4) was obtained from the legal guardian/parent to 
access the medical folder and to perform the examinations. Assent from the 
children was obtained where it was age appropriate. This was dictated by the 
child’s cognitive level as interpreted from the developmental history and 
observation. This study followed the basic needs of all children with HIV-1 
and the interventions are in line with standard practice. At the time of the 
study staffing levels precluded an individual dedicated to managing these 
patients with neurological complications. Following the study, a Neuro-HIV 
clinic has been established at Red Cross Children’s Hospital.  
Ethical approval was obtained from the University of Cape Town, Faculty of 




The data was entered into a Microsoft Excel spreadsheet and analysed using 
standard statistical methods in SPSS Version 10.0, SPSS Inc., Chicago USA. 
Pearson’s correlation coefficient was used to correlate variables. A p-value of 


















Eighty patients were assessed (male n=44: female n=36) (African indigenous 
ancestry n=62; mixed ancestry n=18). Fifty patients were recruited from Red 
Cross Hospital and 30 from Groote Schuur Hospital. The two populations 
were clinically similar. Their ages ranged from 3 months to 12 years (mean: 5 
years 3 months of age, median: 5 years 1 month of age). 
See Figure 1. 
Figure 1 










The parent was the primary care-giver for 50% of patients (40/80), another 
relative was the care-giver for 40% (32/80) and 10% of children (8/80) were 
institutionalised. Thirty patients were orphans. Most patients (75/80) resided 
in urban/peri-urban areas. Forty percent of school eligible children (18/45) 
were in an age-inappropriate lower grade.  
Prior health complications (See Figure 2) consisted of chronic lung disease 
(29/80), disseminated Cytomegalovirus (CMV) infection (5/80) and central 
nervous system opportunistic infections (12/80) (Tuberculous meningitis 5/80, 
Pneumococcal meningitis 2/80, CMV meningoencephalitis 4/80 and 
Progressive Multifocal Leukoencephalopathy caused by JC Virus in 1 
patient). Three patients with confirmed attention deficit hyperactivity disorder 























































 Figure 2 
  Past medical history 
Condition No. of patients 
Chronic Lung disease 29 
Cytomegalovirus infection 5 
CNS opportunistic infections 12 
Attention Deficit Hyperactivity 




On anthropometric assessment, 27 children had a normal weight for age, 39 
children were between 60-80% of expected weight for age (under weight for 
age) and 14 patients were less than 60% of expected weight for age 
(marasmic). See Figure 3 
 
Figure 3  













Stunting (height <90% of expected for age) was documented in 36 patients. 










































Nineteen percent (15/80) of children were microcephalic.  
 
Immune Status 
At the time of the assessment 6 patients were in immunological category 1 
(CD4 % >25%), 15 patients were in category 2 (CD4 % 15-25%) and 59 
patients were in category 3 (CD4 % <15%). See Figure 5 
Figure 5  
Number of participants per immune category at assessment 







































Twenty three percent (18/80) of patients were not on antiretroviral therapy at 
the time of assessment. Eight patients did not meet current guidelines for 
initiation of HAART.27
 
 Ten remaining patients were HAART eligible but 4 had 
defaulted follow-up, 3 were being initiated for treatment (attending adherence 
counseling) and 3 had no explanation. Patients on therapy were prescribed 
different antiretroviral regimens reflecting changes to first line regimens. 
Developmental Screening 
Developmental screening (Figure 6) in patients < 6years of age (n=50) 
identified delay in gross motor skills in 66% of patients (33/50), fine motor 
delay in 75% (31/41), language delay in 70% (29/41), social delay in 56% 
(23/41) and cognitive delay in 73% (25/34) of patients (assessed by the 
child’s ability to count, do mathematical sums, copy figures, relate a story, 
answering questions). Nine infants were too young to be assessed beyond 
their gross motor skills and 16 patients were too young to be assessed for 































Correlation between Immune Categories, Anthropometry, Therapy and  
Neurodevelopment (patients <6 years of age: n=50/80) 
 
Key / Definitions: * = statistically significant; UWFA = underweight for age, 
defined as 60-80% of expected weight; Marasmic defined as less than 60% of 
expected weight for age. Stunted defined as height for age <90% of expected 
for age. 
 
Aberrant Behaviour Checklist 
On the aberrant behaviour checklist (ABC) scale 24 patients had features of 
hyperactivity and 22 patients scored in the mild-moderate range on the 
lethargy / social withdrawal sub-scale consistent with a correlation with the 
affective and adjustment disorders. Children < 1year of age could not be 
assessed for stereotypies and other behaviour problems. 






























2 4 27 12 (80%)*  34 (77%)* 23(76%)* 14 (93%)* 
Fine Motor Delay 1 4 26 8 (53%)  28 (63%) 21(70%)* 11 (73%)* 
Language Delay 
 
4 4 21 9 (60%)*  29 (65%) * 21(70%)* 10 (66%)* 
Social Delay 
 
1 4 18 7(46%)  23 (52%) 18(60%)* 7 (46%) 
Cognitive Delay 
 































Children not treated with 
HAART n=18 
UWFA (n=39) +Marasmic 
(n=14)  
total n=53 




1 2 5 1(5%) 6 (11%) 4(11%) 1/10(10%) 
Lethargy 
 
3 5 14 5(28%) 6 (11%) 6(16%) 1/10(10%) 
Stereotypies 
 
1 1 6 3(16%) 6 (11%) 5(13%) 4/11 (36%)*  
Hyperactivity 
 
3 7 14 2(11%) 17 (32%) 7(19%) 15 (100%)* 
Encephalopathy 2 4 27* 11 (61%)*  
 
33 (62%)* 24(66%)* 15 (100%)* 
 
Key / Definitions: * = statistically significant; UWFA = underweight for age, 
defined as 60-80% of expected weight; Marasmic defined as less than 60% of 
expected weight for age. Stunted defined as height for age <90% of expected 
for age. 
 
Correlation between neurology, immune categories, therapy and 
anthropometry 
Encephalopathy was more common in immune category 3 (CD4 <15%)  
(r value= 0.198)(p=0.026) compared to Immune categories 1(CD4 >25%) and 
2 (CD4 15-25%). Developmental and behavioural problems were also more 
common in immune category 3 than immune categories 1 and 2 but did not 
reach statistical significance (Figures 6 and 7).  
Gross motor delay (r value=0.4) (p=0.002), language delay (r value= 0.62) 
(p=0.005), cognitive delay (r value=0.359) (p=0.03) assessed on the modified 















(r value=0.52) (p=0.027) had a strong correlation with patients not receiving 
HAART (Figures 6 and 7). 
All the patients with HIV encephalopathy were < 80% of expected weight for 
age. Of the patients assessed on developmental screening (patients <6 years 
of age), gross motor delay (77%), language delay (65%), and cognitive delay 
(70%) had a strong correlation with an abnormal weight for age (weight <80% 
of expected for age). On the ABC scales irritability was documented in 6 
patients (r value= 0.143)(p=0.052), lethargy in 6 patients (r value=0.182) 
(p=0.08), stereotypies in 6 patients (r value=0.224)(p=0.122) and hyperactivity 
in 17 (r value=0.012)(p=0.420) of the patients with abnormal weight for age. 
The children who were stunted were statistically more likely to have 
developmental delay in all fields and HIV encephalopathy.  
All patients with microcephaly fulfilled the diagnostic criteria for HIV 
encephalopathy (Figure 7). In the microcephalic group assessed for 
developmental delay, there was statistically significant correlation with gross 
motor delay (14/15) (r value=0.432) (p=0.03), fine motor delay (11/15)  
(r value=0.08) (p=0.05), language delay (10/15) (r value=0.422)(p=0.027) and 
cognitive delay (7/10) (r value=1)(p=0.048). Stereotypies were documented in 
4 patients with microcephaly (r value=0.212) (p=0.006), and hyperactivity 
(n=14 mild, n=1 moderate) in all the patients with microcephaly. There was no 
statistically significant correlation with irritability (r value=0.448) (p=0.107) and 
lethargy (r value=0.554) (p=0.264) and microcephaly.  
 
Neurological Deficits 
Neurological Deficits were identified in 60% of the group. (Figure 8) 
Abnormal neurological findings were global pyramidal tract deficits in 41% of 
patients, hemiparesis in 7%, distal muscle weakness in 6%, proximal muscle 
weakness in 4%, cranial nerve deficits in 4%, visual impairment in 16% and 
hearing impairment in 6% of the cohort. Forty percent of the children had a 


















Neurological Findings on clinical examination 
 
 
Forty one percent of patients (33/80) fulfilled the diagnostic criteria for HIV 
encephalopathy. All of these patients fulfilled criteria B and/or C of the 
definition of HIVE (see above).Eighty one percent (27/33) of this group had a 
CD4 count <15%, 48% (16/33) were infants (<1year old) and 18% (6/33) were 
not receiving antiretroviral agents. 
 
Eleven patients had a history of seizures (idiopathic: n=7, symptomatic: n=4).  
All the patients with seizures had Computerised Tomography (CT) scans of 
the brain performed. In the symptomatic group three were secondary to 
cerebrovascular events and one to CMV meningoencephalitis. Eight children 
had generalized seizures and three partial focal motor. Eight children 
underwent electroencephalogram, of whom three were abnormal (focal 
discharges n=2 and generalised epileptiform discharges n=1). Anticonvulsant 
therapy consisted of carbamazepine (n=1), sodium valproate (n=9) and 
lamotrigine (n=1). 
 
Six patients (7.5%) had cerebrovascular events. Co-morbidities included CNS 
co-infection (2/6) (Pneumococcus n=1, Tuberculous meningitis n=1) and 
Neurological Deficit N=80 
Global Pyramidal Tract signs 33 
Hemiparesis 6 
Distal Muscle weakness 4 
Proximal Muscle Weakness 3 
Cranial nerve deficits 3 
Hearing impairment 5 
Visual Impairment 18 















thrombocytopaenia in one patient. Vasculitic and pro-thrombotic screens were 
negative in all these patients. 
 
Four patients had pain and distal weakness. Their nerve conduction studies 
confirmed axonal peripheral neuropathies. Three of these patients were 
receiving stavudine (d4t) and 1 patient had a positive CMV PCR result. 
 
Investigations 
Because of financial constraints neuro-imaging was only performed as 
indicated by the clinical needs of the patient. Computerised tomography 
scans of the brain performed in 26 patients demonstrated cerebral atrophy in 
11 patients, calcification in 5 patients (periventricular n=2 and basal ganglia 
n=3), cerebral infarcts in 8 children and 2 scans were normal. One patient 
who had JC Virus isolated on CSF underwent magnetic resonance imaging 
(MRI) which demonstrated white matter lesions consistent with progressive 
multifocal leukoencephalopathy (Figure 9). Sixteen patients underwent 
lumbar punctures. Four of these patients had elevated CSF protein levels 
(median 0.63g/l normal range- 0.15-0.45g/l) and lymphocytosis identified as 
part of a diagnostic work-up for developmental delay. Twelve patients 
underwent CSF examination for suspected opportunistic CNS infections (10 
patients had raised CSF protein levels median figure= 0.72g/l, 2 had 
lymphocytosis and 1 had polymorph predominance).  The opportunistic 
organisms isolated were Streptococcus Pneumonia n=2, JC Virus n=1 and 
CMV (confirmed via polymerase chain reaction (PCR) positive on CSF) n=4. 
Tuberculous Meningitis (TBM) was suspected in 4 patients based on 
additional supporting diagnostic tests (Mantoux skin test, Chest radiograph, 
and a TB contact history). Based on clinical suspicion of hearing impairment, 
5 patients who had Brainstem auditory evoked responses had evidence of 
sensorineural hearing impairment following meningitis in two and of unknown 



















Figure 9: Axial T2 Image of patient with Progressive Multifocal 
Leukoencephalopathy demonstrating sub-cortical and periventricular white 
matter hyperintensities of predominantly the frontal lobes 
 
Discussion 
Sixty percent of our patients had neurological complications. This cohort was 
recruited from dedicated infectious diseases clinics and was representative of 
children from specialized and community services in South Africa. This study 
confirmed that neurological disease in these patients is underestimated and 
their care not optimized. 
 
HIV Encephalopathy (HIVE) is the hallmark of developmental disabilities in 
HIV infected children. It is categorized as an AIDs defining condition i.e. a 
clinical (Category C) condition in the Centers for Disease Control and 















than 13 years of age.24 Based on the World Health Organization (WHO) 
clinical staging system HIVE is listed as a WHO stage 4 disorder.28 The broad 
spectrum of clinical manifestations and severity of CNS disease associated 
with HIVE lead to the development of a classification system for HIVE, 
currently used at the HIV and AIDS Malignancy Branch of the National 
Cancer Institute of the National Institute of Health.
 
29 
HIVE is defined as either progressive (sub-acute or plateau), or static.29, 30 
Progressive HIV encephalopathy (PHE) is the most severe subtype often 
seen in children who are naïve to antiretroviral therapy. The features of this 
disorder are impaired brain growth, progressive motor dysfunction and loss or 
plateau of the acquisition of age-appropriate developmental milestones.29, 31 
The course of the plateau type of encephalopathy is more indolent with either 
the absence of acquisition of new skills or a slower rate of acquisition of new 
skills.31 Children with static encephalopathy tend to have fixed 
neurodevelopmental deficits with no loss of skills.
 
31 
Forty one percent of our cohort (n=33/80) fulfilled the diagnostic criteria for 
HIVE. Forty eight percent of this group were under the age of 1yr, which is 
comparable with other reports.32,33 Early onset of neurological symptoms and 
signs (<1yr) in HIV infected children has a different pathophysiology than 
those in older children.34 When children from the French Perinatal Cohort 
were compared with the French SEROCO adult cohort the cumulative 
incidence of encephalopathy was higher in children only during the first and 
second years of life suggesting a pre-natal onset of brain infection in the sub-
group of patients with early onset of neurological signs.34 Children in whom 
signs of encephalopathy appear in the first year of life have greater severity 
and shorter survival than those in whom encephalopathy appears later.35 
Reflecting other studies, our patients with more severe immunosuppression 

















Neurodevelopmental deficits are evident in children with severe HIV 
encephalopathy.  In children with severe HIV encephalopathy the effects are 
global i.e. in all neurodevelopmental domains. In the less advanced stages of 
the disease selective functions maybe differentially affected.37 Speech and 
language deficits may appear early.37 Language assessment has been 
suggested as a useful tool to determine the best time to initiate therapy or to 
monitor treatment.38 In our cohort 70% of patients had language delay. This 
was similar to the rates of gross motor delay (66%), fine motor delay (75%) 
and cognitive delay (73%) in our patients. Motor impairment is also frequently 
found in HIV CNS disease.39 The rate of gross motor deficits in our cohort 
was higher than described in other studies.32 Motor deficits are also seen 
more frequently in children <1yr of age.32 
Other factors contributing to neurodevelopmental delay in this population 
include malnutrition, environmental deprivation, co-morbid chronic infections 
and prolonged hospitalisation.  
This is borne out in our cohort 
where 65% of the patients with gross motor delay were <1yr of age. 
 
Growth failure and malnutrition are common in HIV-1 infection due to poor 
caloric intake, chronic diarrhoea, oro-motor inco-ordination, and recurrent 
infections. 
Children with impaired growth may have a low weight for age (60-80% of 
expected weight for age: underweight for age, <60% expected weight for age: 
marasmic) or a low height for age (height for age <90% expected for age: 
stunting).
40 
41 Stunting is an indication of slow skeletal growth and a well 
established child health indicator of poor socio-economic conditions, chronic 
or repeated infections as well as chronic malnutrition. 
 
42  
Children who are chronically malnourished exhibit behavioural changes, 
including irritability, apathy, reduced social responsiveness, anxiety, and 
attention deficits.43 In addition, infants and young children who have 
malnutrition frequently demonstrate delay in achievement of motor skills, 















Dose-dependent relationships between impaired growth and poor school 
performance and decreased intellectual achievement are reported. 44,45 The 
correlation between malnutrition and developmental delay has also been 
demonstrated in patients post liver transplantation.46  Malnutrition has also 




We found a statistically significant correlation between children who were 
underweight for age (UWFA) or stunted and delayed in all developmental 
domains, behavioural problems and encephalopathy. Pollack et al found that 
HIV-1 infected infants with more pronounced growth failure had the most 
marked cognitive and motor delay.48 Wiznia et al reported a correlation 
between poor weight for age and decreased cognitive function.49 Missmer et 
al found that stunting was a strong predictor of decreased functional status.50
 
  
Microcephaly is one of the diagnostic criteria for HIV encephalopathy. 
Microcephaly is an indicator of impaired brain growth and cortical atrophy, 
usually secondary to HIV encephalopathy. Cortical atrophy is associated with 
disease progression and neuro-developmental delay.35
Growth parameters are important markers of disease progression in HIV 
infected children and may be predictive of neurodevelopmental status.
 In our cohort children 
there was a strong correlation between children with microcephaly and 
developmental delay and hyperactivity. 
 
31 
Behaviour problems were reported in 28 patients. The high rate of patients 
scoring in the mild-moderate range for the sub-scale lethargy / social 
withdrawal (n=22) reflects a correlation with the affective and adjustment 
disorders but could also be a symptom of the chronic debilitating illness in this 
cohort. Patients who scored in the mild range on the stereotypies sub-scale 
(n=8) correlated with organic brain syndromes and pervasive developmental 
disorders. Those in the irritability sub-scale (n= 8) correlated with oppositional 















reported to have more frequent behavioural problems and developmental 
delay compared to established childhood norms.51 The key behaviour 
problems described were psychosomatic (28%),  learning difficulties (25%), 
hyperactivity (20%), conduct (16%), and anxiety (8%).51 Prevalence rates of 
28.6% for attention deficit/ hyperactivity disorder (ADHD), 24.3% for anxiety 
disorders and 25% for depression are reported.52-56 In our cohort 30% of 
patients scored in the mild–moderate hyperactivity spectrum. This percentage 
is higher compared to ADHD in the general population (3-5%) and to children 
with other chronic medical conditions associated with behavioural problems.
A variety of aetiologies have been proposed for these problems. These 
include direct effects of the HIV on the frontal cortex and basal ganglia- 
structures associated with regulation of behaviour, attention and 
concentration.
57  
58 In addition, the children may also have other medical and 
environmental risk factors that may contribute to neuro-behavioral 
abnormalities. Environmental factors affecting families living with HIV include 
poverty, violence, overcrowding, nutritional status, frequent hospitalization 
and single-parent households.59 In our group of patients 10% were 
institutionalized and 40% were not being cared for by a parent. Such factors 
would likely increase the risk of psychological difficulties. Maternal HIV also 
has an impact on children’s emotional and behavioural functioning.
 
59 
HAART produces a positive and sustained effect on neuro-cognitive 
impairment in HIV infected patients.60 When HAART is commenced during 
early infancy, the prevalence of CNS effects may be reduced to less than 
2%.61 Our patients without treatment had significantly greater rates of 
developmental delay and HIVE. Although HAART reverses some of the 
damage caused by the virus, residual features of arrested HIV 
encephalopathy may persist with behavioural problems, neurological and 
cognitive deficits62
The public sector ART programme in South Africa commenced in April 2004, 
but access to therapy for children remained limited during the first few years 
of the programme. Therapy was often commenced in children with 















established neurological disease and the impact from this delay evident in the 
limited reversibility of disease. 
 
Cerebrovascular events have an annual incidence of 1.3% in HIV infected 
children; this figure is thought to be highly underestimated.15 Strokes are the 
commonest cause of focal neurological deficits in children with HIV 
infection.63 Strokes in HIV infection may be secondary to hemorrhage 
resulting from HIV related thrombocytopaenia15 as occurred in one patient in 
our series. Infarct related strokes may result from pro-thrombotic states, often 
due to protein S deficiency64 or a vasculopathy. Vasculopathy maybe 
secondary to the HIV virus which is known to cause a segmental aneurysmal 
dilatation of the arteries of the circle of Willis associated with destruction of 
the elastic lamina and focal thrombotic occlusion15 or due to other 
opportunistic infections. In our group two cerebrovascular events were 
thought due to vasculitis secondary to a co-infection (Streptococcus 
Pneumonia n=1, Tuberculous meningitis n=1). By exclusion of other risk 
factors the cause of the stroke in the remaining three patients was presumed 
due to HIV related vasculopathy. An association between Moyamoya disease 
and HIV is described in adults65and a child.66 Both HIV-mediated cytokine 
responses and HAART have been implicated in causing cerebrovascular 
disease and the Moyamoya phenomenon.67
 
   
Neuromuscular complications, often considered uncommon in HIV positive 
children may be under-estimated due to the difficulty in diagnosing 
neuromuscular disorders in chronically ill, non-verbal children. The aetiology 
of neuromuscular complications in HIV infection is multi-factorial and maybe 
due to the neurotoxicity of antiretroviral drugs in association with immune-
mediated mechanisms triggered by HIV infection, the sequelae of chronic 
illness and opportunistic infections.  
The prevalence of peripheral neuropathies is quoted as about 5%.68 The 
mechanisms of neuropathy are secondary to immunological dysregulation 















analogues (didanosine, d4T) that inhibit reverse transcriptase. In our cohort, 
three of the four affected patients were on d4T. Recent evidence supports 
mitochondrial toxicity as a principal mechanism for didanosine and d4T-
associated neuropathy. 69 Opportunistic infections like CMV and Varicella 
zoster virus are also implicated in a lumbo-sacral polyradiculoneuropathy. 70
In a comprehensive series described by the National Institute of Health, an 
axonal peripheral neuropathy was described in 12/50 HIV positive children. 
 
One affected patient in our cohort had a CMV PCR that was positive. 
71 
Another series also described axonal neuropathy as the commonest sub-type 
in HIV associated neuropathy.72
 
 All the patients in our cohort with peripheral 
neuropathy also demonstrated an axonal degenerative pattern of injury. 
Seizure disorders are reported in about 16% of children with HIV related 
CNS disease.73 Epilepsy is usually secondary to other complications (such as 
opportunistic infections and febrile illnesses) rather than due to HIV CNS 
disease.13 The concurrent use of anticonvulsants and antiretrovirals poses a 
therapeutic dilemma for the clinician caring for HIV-positive patients requiring 
both groups of medications. Concomitant antiretroviral-anticonvulsant use has 
been associated with both increases and decreases in anticonvulsant 
concentrations, loss of viral suppression, and decreased concentrations of 
antiretrovirals.74 These drugs may interact through multiple mechanisms 
including competition for protein binding and enhanced or reduced liver 
metabolism (interactions with cytochrome P450 system). One of the patients 
in our group was concomitantly on carbamazepine and a protease inhibitor 
(PI). Because carbamazepine induces the enzymes of the P450 system 
concomitant use with a PI may result in sub-therapeutic ARV levels and 
treatment failure, as well as potential resistance to the PI class of drugs.75
Our unit recommends the use of sodium valproate for HIV-infected children 
on ARVs. However this agent also interacts with several of the ARVs 
especially efavirenz, ritonavir and zidovudine via induction of CYP450 
isoenzymes.
 PIs 
may, in turn, cause toxic levels of anticonvulsants. 















enfuvirtide reduces the pool CD 4 cells which are latently infected with HIV 
raising the possibility, in theory, of a cure for HIV. Follow-up studies have not 
supported this theory to be of clinical efficacy.
 
77,78 
CNS opportunistic infections occurred in 15% of our cohort.  
South Africa has one of the five largest national TB epidemics in the world; 
the estimated incidence rate was 948 / 100,000 population / annum in 2007.79 
The TB incidence rate has increased dramatically as the HIV epidemic has 
worsened, with the number of TB cases more than doubling since 1996. In 
our cohort 4 children were previously treated for TB meningitis. Tuberculous 
meningitis is the commonest type of bacterial meningitis admitted to one 
centre in the Western Cape of South Africa.80 HIV/ TB co-infection has 
implications for disease progression and management. Immunosuppression, 
due to HIV, predisposes the patient to dissemination of M. tuberculosis 
(MTB). Tuberculosis is thought to increase HIV replication and viral load.81 
The mechanisms by which these interactions are thought to occur are due to 
both promoter enhancement and cytokine activity playing key roles in the 
heightened HIV activity seen in the presence of M. tuberculosis.81, 82 
Tuberculosis may reactivate latent HIV in monocytes recruited to the site of 
the MTB infection via a stimulatory transcription factor83 and latent HIV 
reservoirs are thus established at sites of MTB infection.84 There is also 
evidence that TB increases systemic HIV heterogeneity85
Streptococcus Pneumoniae and Haemophilus Influenza Type B are 
pathogens which frequently cause bacterial meningitis in HIV-infected 
children. 
 which has 
implications for resistance to antiretroviral drugs. Managing co-infection with 
TB is complicated by the drug-drug interactions and the interaction of both 
classes of drugs on the cytochrome P450 system. 
86 Progressive multifocal leukoencephalopathy (affecting one patient 
in our series) is reported in 14% of adults with AIDS87 but infrequently in HIV-
infected children. CMV is described as the commonest opportunistic infection 
in HIV-infected children.88 CMV causes both primary neurological syndromes 















activation of HIV in the brain.88
None of the patients in our cohort had a CNS lymphoma, however this 
complication does occur in our population.
 In our series 5 patients (6%) had CMV co-
infection.  
 
89   
Neuroimaging has been used as an objective measure of ongoing brain 
injury and of the response to ARVs.90 Children with HIV infection may have 
neuro-imaging abnormalities due to HIVE (cerebral atrophy, 
leukoencephalopathy, basal ganglia calcification) or secondary to 
complications from being immunocompromised (infarcts, malignancies, 
infections). The prevalence of CT abnormalities of any type has varied from 
63% to 86%.91, 92 In our cohort 11 patients had evidence of cerebral atrophy 
on neuro-imaging. The degree of cerebral atrophy has also been correlated 
with scores on neuropsychological tests.
Imaging abnormalities were identified in 76% of patients classified as non-
encephalopathic
93 
94 and hence could be used as a marker to initiate 
antiretroviral therapy early in the disease course. The commonest CT 
abnormalities are ventriculomegaly, cerebral atrophy, white matter changes 
and basal ganglia calcification, as occurred in our cohort.94 
 Of the patients who had CT scans of the brain performed 11% had evidence 
of basal ganglia calcification. Other series have reported 61% of patients 
having basal ganglia calcification.95 Post-mortem studies95 have shown 
variable degrees of calcific vasculopathy of the basal ganglia. Other studies 
have shown varying degrees of blood-brain-barrier disruption with associated 
oedema and inflammation in the basal ganglia at the time when basal ganglia 
calcification was documented on neuro-imaging.96 Calcification is seen 
primarily in vertically infected children and may indicate a selective 
vulnerability of the basal ganglia of the developing brain to HIV infection. All 
our patients with basal ganglia calcification had HIVE. This has been reported 
in another series. 
In resource limited settings CT imaging is more accessible than MRI. 
















are no financial constraints. Magnetic resonance imaging and more 
specifically volumetric MRI are more sensitive and specific in assessing HIV 
associated brain changes. Proton MRS Studies in adults with HIV infection 
are consistent with neuronal cell loss and inflammation some of which is 
shown to be reversible with antiretroviral therapy on follow-up studies.
 
97, 98 
This study had some limitations. The neurodevelopmental deficits and 
behaviour problems identified can not be considered as solely related to HIV 
infection due to the complex socio-economic profile of the participants, 
including orphan status, limited maternal education and malnutrition. We lack 
a comparison group to control for environmental factors. Peri-natal factors 
such as prematurity and other perinatal insults were not taken into 
consideration in the interpretation of the results of the neurological and 
developmental assessments.  
The developmental screening was not performed via formalized tools but 
more history related and by observation and modified from the Denver ll 
Developmental Screening test. The limitations of using this scale are that it is 
used as a crude screening tool to identify only severe problems; and it could 
only be applied to children < 6years of age.  This simplified method was 
incorporated to recruit more patients with minimal impact to their clinic time 
attendance. Cognitive and fine motor assessments could not be done in 
infants and this is taken into account in the analysis of the data.  The wide 
age range also limits interpretation of some of the data.  As a result the 
developmental findings should be treated with some caution.  
The use of an interpreter when administering the ABC scale, could have 
introduced a bias and since the care-givers had different levels of literacy 
their interpretation of the questions and insights may have varied. The ABC 
was translated verbally during the assessment by the interpreter. 
The small sample in this study limits the potential to generalise the findings. 
The patients recruited at the Red Cross Hospital clinic may represent a 
biased sample as some complex patients are referred from secondary level 















duration of treatment prior to the assessment is not taken into account and 
this could also lead to bias.  
 
Conclusion 
Neurological complications of HIV are common and span a wide spectrum of 
disorders. The impact of HIV related CNS neurocognitive dysfunction is a 
challenge that is compounded by co-morbidities and the complex socio-
economic problems in South Africa and other resource limited settings. Poor 
socio-economic status, low birth weight, anaemia, malnutrition, childhood 
encephalopathies such as tuberculous meningitis and other bacterial 
meningitides as well as the effects of maternal AIDS on the child are all 
confounding factors affecting the neuro-developmental and behaviour 
outcomes in a child afflicted with HIV. These variables pose a major 
challenge in determining the incidence of HIV-attributable CNS disease in 
children99 
Although progress has been made in increasing ART access to South African 
children with HIV infection, many children start ART late and a sizable 
proportion who need ART are still not receiving therapy. Consequently, HIV 
related neurocognitive disability remains a significant problem because of 
these challenges and the limited access to regimens with the highest efficacy 
in penetrating the blood-brain barrier. In current practice PHE is an ARV 
eligibility criterion, comprehensive neurological, developmental and 
behavioural assessment though, is rarely performed in resource-limited 
settings due to a shortage of skilled staff. This compounds the delays in 
initiating HAART and other strategies for care of HIV-associated 
neurodevelopmental impairment.  Socio-economic problems may prevent 
patients attending clinics to collect medication. 
and illustrate the layering effects of multiple pathologies influencing 
clinical phenotypes. 
All patients with persistent developmental delay and abnormal neurological 

















There is a need for further longitudinal studies on the neuro-developmental 
complications of HIV. Populations with access to HAART are surviving into 
adolescence; these groups need to be studied to understand their long-term 
neurological and neuropsychological complications. The impact of persistent 
neurodevelopmental sequelae on education, employment and social 
integration is of increasing importance as children treated with HAART 
survive into adulthood.100 
 
With improved understanding of the risks inherent in 
HIV related illnesses, effective medical and psychosocial interventions can be 
implemented early to improve health and quality of life of these children. In 
addition intervention studies are urgently needed to establish the best way to 
manage the complex, multi-faceted psychosocial and developmental needs of 
these children.  
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Appendix 1: Group demographics 
Date of examination 
  
Age in months  
 
Gender                                                   Ancestry  
 
On HAART if yes itemise  
 
Date of commencement  
 
CD4 at diagnosis (DIAG)                       at start ART                       most recent (date)  
 
Viral load DIAG                                    start of ART                      most recent (date)  
 
COH at DIAG cms / centile                  start of ART                       most recent (date)  
 






























Care giver e.g.: granny, biological mom, foster: 
Address, i.e.: family home or institution: 
 




Grade age appropriate 
Teacher’s report if available 
Perinatal and relevant PMH
 
 (e.g. HIE, tuberculosis): 
PREVIOUS INVESTIGATIONS OF RELEVANCE 
 
(e.g. CT, EEG, audiology): 





EMOTIONAL STATUS                         
 Never documented:                       
 Happy, sad, aggressive, labile etc:      
SEIZURES 
BEHAVIOURAL PROBLEMS 
 Date documented:                              
 



















 Age in months : 
 Head Circumference ( COH):  
 Weight : 
 Height : 
 Mood: happy, sad, irritable, cross etc 
 general behaviour, playful, busy, hyperactive, 
withdrawn etc  
 MOTOR 
power  UL R                           L 
             LL R                           L 
 Proximal VS Distal 
Tone Central                                  Appendicular 
Deep tendon reflexes: brisk, depressed     UL R                           L 
                                                                       LL R                           L 
Superficial reflexes Plantars                Abd 
  
 Sensory 
 Light touch 
 Pain 
 Posterior column 
  
 Abnormal movements 
 cerebellar  signs : finger pointing, ataxia, 
nystagmus 
 cranial nerves  


















Appendix 2: Norms of development (Modified from Denver 2 Developmental Screen)     
Age in months:            Activity                                                                       present                   Normal range  
                                    Lifts chin off coach when prone       
                                   Smiles responsively  
 
                                   Stills or startles to sounds                                                                         2 months  
                                                 Regards own hand                                       
                                   Supine lie head central  
 
                                    Vocalizes                                                                                                   2- 4 months   
                                                Turns to Voice 
                                  No head lag when pulled to sit 
                                   Grasps with whole hand   
 
                                                 Laughs                                                                                             4-6 months    
                                               Waves Bye-bye                                                       
                                              Sits securely  
                                              Feeds self with biscuit 
 
                                              Jabbers/Babbles- non-specific                                                                       6-8 months  
                                              Indicates wants 
                                             Crawls     
                                              Points with index finger 
 

















                                              Drinks from a cup 
                                              Scribbles 
                                              Walks with support  
                                 
                                             2-3 words with meaning                                                                                10-12 months  
                                              Assists with removing clothes 
                                              Walks unaided at least 10 steps                                               
                                              Scribbles 
 
                                              3-4 single words with meaning                                                                   12-18 months  
                                              Up steps/ runs 
                                              Uses a spoon  
                                              Puts on clothes 
 
                                              Combines 2 words                                                                                        18-24 months  
                                              Washes hands 
                                              Jumps 
                                              Imitates vertical line 
                              Dry during day  
                                                                                                                                                  
                                              Sentences 3-4 words/knows name                                                              24-36 months 
                                              Dresses 
                                              Stands on one leg 2 seconds 
                                              Counts to four 
                                              Copies circle 
 
















                                              Brushes teeth 
                                              Catch a ball 
                                              Tells his age 
                                              Counts to 10 
                                              Copies a cross 
                                              Draw a person- 3 parts 
 
                                              Knows 4 colours                                                                                                 4-5years          
                                              Draws man 6 parts 
                                              Knows morning from pm 
                                              Copies square 
                                              Knows opposites 
 



























ABERRANT BEHAVIOR CHECKLIST-COMMUNITY 
Client’s Name:                                                Rater’s Name: 
Client’s Gender:                                              Relationship to Client: Parent 
Date of Birth:                                                                                       Teacher 
Today’s date:                                                                                       Trainer/ Supervisor 
                                                                                                             Other (Specify) 
Where was the client observed: Home 
                                                    School 
                                                    Residential Unit 
                                                    Workshop 
                                                    Other (Specify) 
If in School-Type of Class          Developmentally Handicapped 
                                                   Multi-handicapped 
                                                   Severe Behavior Handicapped 
                                                    Other 
Race Group   Caucasian 
                       African- American 
                       Hispanic 
                       
                        Other 
CLIENT’S MEDICAL STATUS 
A. Deafness                                   Yes                                      No                               Don’t know 
B. Blindness                                   Yes                                      No                               Don’t’ know                                                   
C. Epilepsy                                     Yes                                      No                               Don’t know 
D. Cerebral Palsy                           Yes                                      No                               Don’t know 
E. Other                                           Yes                                    No                               Don’t know 






A1989 Slosson Educational Publications, Inc.                                     Additional Copies available from 
Rights Reserved                                                                                   SLOSSON EDUCATIONAL PUBLICATIONS 
 





















The ABC Community Rating Scale is designed to be used with clients living in the community. Please note that the 
term client is used throughout to refer to the person being rated. This may be a child of school age, an adolescent, or 
an adult. 
Please rate the client’s behavior for the last four weeks. For each item, decide whether the behavior is a problem and 
circle the appropriate number: 
                                              0 = not at all a problem 
                                              1= the behavior is a problem but slight in degree 
                                              2 = the behavior is moderately serious 
                                             3 = the problem is severe in degree 
a. 
When judging the client’s behavior please keep the following points in mind: 
b. 
Take relative frequency into account for each behavior specified. For example if the client 
averages more temper outbursts than most other clients you know or most others in his/her 
classes, it is probably moderately serious (2) or severe (3) even if these occur only once or twice 
a week. Other behaviors such as non-compliance, would probably have to occur more frequently 
to merit an extreme rating. 
c. 
If you have access to this information, consider the experiences of other care providers with this 
client. If the client has problems with others but not with you, try to take the whole picture into 
account. 
 
Try to consider whether a given behavior interferes with his/her development /functioning or 
relationships. For example body rocking or social withdrawal may not disrupt other children or 
adults, but it almost certainly hinders individual development or functioning. 
Do not spend too much time on each item-your first reaction is usually the right one. 
1. Excessively active at home, school, work or elsewhere          0             1            2            3 
2. Injures self on purpose                                                            0              1           2            3 
3. Listless, sluggish, inactive                                                       0              1           2            3 
4. Aggressive to other children or adults (physically or verbal)   0              1           2            3 
5. Seeks isolation from others                                                     0              1           2            3 
6. Meaningless recurring body movements                                0               1           2            3 
7. Boisterous (inappropriately noisy and rough)                         0               1           2            3 
8 Screams inappropriately                                                          0               1           2            3 
9. Talks excessively                                                                    0               1           2            3 
10. Temper tantrums/outburst                                                    0                1          2             3 
___________________________________________________________________________ 
11. Stereotyped behavior, abnormal, repetitive movements      0                1          2             3 
12. Preoccupied stares into space                                             0                1          2             3 
13. Impulsive (acts without thinking)                                          0                1          2             3  
14. Irritable and whiny                                                                0                1          2             3 
15. Restless, unable to sit still                                                    0                1          2             3  
16. Withdrawn prefers solitary activity                                        0                1          2             3 
17. Odd bizarre behavior                                                            0                1          2             3 
18. Disobedient difficult to control                                              0                 1         2              3 
19. Yells at inappropriate times                                                  0                 1         2              3 

















21. Disturbs others                                                             0               1                 2                3 
22. Repetitive speech                                                         0               1                 2               3 
23. Does nothing but sit and watch others                          0               1                2                3 
24. Uncooperative                                                               0               1                2                3  
25. Depressed Mood                                                           0               1               2                 3 
26. Resists any form of physical contact                             0               1               2                 3 
27. Moves or rolls head back and forth repetitively             0               1               2                 3 
28. Does not pay attention to instructions                           0               1               2                 3 
29. Demands must be met immediately                             0                1              2                  3  
30. Isolates himself/herself from other children or adults   0                1              2                  3 
 
__________________________________________________________________________________________ 
31. Disrupts group activities                                            0                 1               2                 3 
32. Sits or stands in one position for a long time            0                  1              2                  3    
33. Talks to self loudly                                                    0                   1             2                  3 
34. Cries over minor annoyances and hurts                   0                   1             2                  3  
35. Repetitive hand, body or head movements              0                   1             2                  3 
36. Mood changes quickly                                              0                   1             2                  3 
37. Unresponsive to structured activities (does not react) 0                1            2                   3 
38. Does not stay in seat                                                   0                1             2                  3 
39. Will not sit still for any length of time                           0                1             2                  3 
 
40. Is difficult to reach, contact, or get through to             0                 1            2                  3 
 
      41. Cries and screams inappropriately                           0                  1             2                 3 
      42. Prefers to be alone                                                   0                   1            2                 3 
      43.  Does not try to communicate by words or gestures0                   1            2                 3 
      44. Easily distractible                                                    0                    1             2                 3 
      45. Waves or shakes the extremities repeatedly          0                    1             2                 3 
      46. Repeats a word or phrase over and over               0                     1            2                 3 
      47. Stamps foot or bangs objects or slams doors        0                     1            2                 3 
      48. Constantly runs or jumps around the room            0                     1            2                 3 
      49. Rocks body back and forth repeatedly                  0                     1             2                 3  
 
      50. Deliberately hurts himself/herself                          0                     1              2                3 
 
51. Pays no attention when spoken to                             0                     1               2                 3 
52. Does physical violence to self                                    0                     1               2                 3 
53. Inactive, never moves spontaneously                        0                      1              2                 3 
54. Tends to be excessively active                                   0                      1              2                 3 
55. Responds negatively to affection                                0                      1              2                 3  
56. Deliberately ignores directions                                   0                       1              2                 3  
57. Has temper outbursts or tantrums                             0                        1              2                3 
      when he /she does not get own way          



















Parent/legal guardian:  
 
I--------------------------------------- the parent/legal guardian (delete whichever is not applicable) of -----------------------------
------------- give my consent for the records of this child to be used for research regarding HIV infection in children. I 
also consent for clinical examinations to be recorded for study purposes. I understand that confidentiality will be 
respected. I voluntarily give consent -------------------- to participate in studies concerned with HIV infection in children. 
I am free to withdraw my child if I wish. The aim of this study is to improve the overall management of all children 
who are HIV positive  
 
 
Signature  
 
Date  
 
Witness  
 
Signature 
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